Corona Remedies Ltd EPS

Corona Remedies Ltd EPS

Image

Corona Remedies Ltd

NSE: CORONA

EPS

₹ 32.68

Last updated on: Jul 28, 2026

Key Highlights

  • The Earning per Share of Corona Remedies Ltd is ₹ 32.68 as of 28 Jul 26 The earning per share of Corona Remedies Ltd changed from ₹ 4.9 to ₹ 7.41 over 8 quarters. This represents a CAGR of 22.97% .

Historical Earning per Share of Corona Remedies Ltd

No data available

* All values are in

Company Fundamentals for Corona Remedies Ltd

Market Cap

12,653 Cr

EPS

32.7

P/E Ratio (TTM)

63.3

P/B Ratio (TTM)

16.9

Day’s High

2125.0

Day’s Low

2071.0

DTE

0.2

ROE

24.8

52 Week High

2139.55

52 Week Low

1336.95

ROCE

27.1

Market Price of Corona Remedies Ltd

1M

1Y

3Y

5Y

Monitoring Corona Remedies Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
28 Jul 20262068.95
27 Jul 20262094.05
24 Jul 20262114.1
23 Jul 20262027.4
22 Jul 20262042.6
21 Jul 20262089.15
20 Jul 20262042.35
17 Jul 20262068
16 Jul 20262067.25
15 Jul 20262064.55

SWOT Analysis Of Corona Remedies Ltd

Strength

1

che

Weakness

1

che

Opportunity

0

che

Threats

0

che

BlinkX Score for Corona Remedies Ltd

Asset Value vs Market Value of Corona Remedies Ltd

Market Value

12,654

Asset Value

Value addition

32.4 X

379

* All values are in ₹ crores

Competitive Comparison of EPS

Company
leftMarket Capright
Corona Remedies Ltd12653
Sun Pharmaceutical Industries Ltd474397
Divis Laboratories Ltd196990
Torrent Pharmaceuticals Ltd186354
Cipla Ltd116705
Zydus Lifesciences Ltd109686

Historical Market Cap of Corona Remedies Ltd

No data available

* All values are in crore

Historical Revenue of Corona Remedies Ltd

No data available

* All values are in crore

Historical EBITDA of Corona Remedies Ltd

No data available

* All values are in crore

Historical Net Profit of Corona Remedies Ltd

No data available

* All values are in crore

Dividend Payout Over Time

No data available

Corona Remedies Ltd News Hub

Corona Remedies to announce Quarterly Result

Corona Remedies will hold a meeting of the Board of Directors of the Company on 31 July 2026.

Read more

18 Jul 26

Shares of Corona Remedies list in B group

The equity shares of Corona Remedies (Scrip Code: 544644) are listed effective 15 December 2025 and

Read more

15 Dec 25

Corona Remedies Q2 PAT climbs 22% YoY to Rs 52 cr

Profit before tax (PBT) increased 21.67% year on year (YoY) to Rs 69.78 crore in Q2 FY26. Earnings B

Read more

03 Jan 26

Corona Remedies gains as Q2 PAT climbs 22% YoY to Rs 52 cr

Profit before tax (PBT) increased 21.67% year on year (YoY) to Rs 69.78 crore in Q2 FY26. Earnings B

Read more

05 Jan 26

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for EPS of Corona Remedies Ltd

What is the EPS of Corona Remedies Ltd stock?

The Earnings Per Share (EPS) of Corona Remedies Ltd is 32.68. An EPS is the amount of net income attributed to each share of a common stock.

How is Corona Remedies Ltd EPS calculated?

The EPS of Corona Remedies Ltd is calculated by dividing the net income by the number of outstanding shares. The formula is EPS = (Net Income - Dividends on Preferred Stock) / Average Outstanding Shares.

How often does Corona Remedies Ltd report its EPS?

Corona Remedies Ltd typically reports its EPS quarterly and annually, in conjunction with its financial statements and earnings reports.

What factors can influence Corona Remedies Ltd EPS?

Factors that influence the EPS of Corona Remedies Ltd include revenue changes, cost fluctuations, operational efficiency, tax rates, and one-time gains or losses.

Can Corona Remedies Ltd EPS growth indicate future performance?

Yes, consistent growth in Corona Remedies Ltd EPS can suggest strong financial health and effective management, potentially indicating positive future performance.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions